Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cerebroprime is a nutraceutical supplement marketed by Primus Remedies. It is formulated as an oral tablet containing 90 mg of cerebroprotein hydrolysate combined with essential vitamins. Cerebroprotein hydrolysate is a mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine brain tissue. It acts as a neuroprotective and neurotrophic agent, mimicking the effects of endogenous neurotrophic factors (such as BDNF, NGF, GDNF, and CNTF) to support neuronal survival, enhance neuroplasticity, and promote cognitive recovery. Cerebroprime is used to support brain health and manage cognitive decline associated with neurological conditions such as stroke, traumatic brain injury, Alzheimer's disease, and vascular dementia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cerebroprime.